10-Q: Chemed Corp. Q2 2026 Earnings: Revenue Up, Profit Growth Driven by VITAS

Chemed Corporation reported Q2 2026 results with an 8.8% increase in consolidated service revenues and sales, driven by strong performance in its VITAS hospice care segment.

Summary

• Chemed Corporation reported Q2 2026 results, with consolidated service revenues and sales increasing by 8.8% to $673.3 million compared to the prior year period.
• Net income rose to $67.7 million, or $5.13 per diluted share, up from $52.5 million, or $3.57 per diluted share, in Q2 2025.
• The VITAS segment saw revenue growth of 11.9% to $443.3 million, primarily due to a 6.1% increase in days of care and a 2.4% rise in Medicare reimbursement rates.
• Roto-Rooter's net revenue increased by 3.3% to $229.9 million, driven by growth in plumbing, drain cleaning, and excavation services, partially offset by a decrease in water restoration.
• The company completed four acquisitions for Roto-Rooter in Q2 2026, contributing to a $32.4 million increase in goodwill.
• Chemed repurchased $89.8 million of its stock in Q2 2026, with $139.8 million remaining under its authorized share repurchase program.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue and profit growth driven by the stable VITAS segment, despite some cost pressures and segment-specific challenges in Roto-Rooter.

Positives

• Consolidated service revenues and sales increased by 8.8% to $673.3 million in Q2 2026.
• Net income grew by 29% to $67.7 million in Q2 2026.
• Diluted EPS increased to $5.13 in Q2 2026 from $3.57 in Q2 2025.
• VITAS segment revenue grew by 11.9% to $443.3 million, driven by increased days of care and higher reimbursement rates.
• Roto-Rooter segment revenue grew by 3.3% to $229.9 million.
• VITAS gross margin improved to 23.8% in Q2 2026 from 19.1% in Q2 2025.
• Roto-Rooter gross margin improved to 50.4% in Q2 2026 from 49.0% in Q2 2025.
• The company has $262.7 million of unused lines of credit available.

Negatives

• Roto-Rooter's water restoration revenue decreased by 6.0% and contractor operations decreased by 1.9% in Q2 2026.
• Corporate expenses increased by 42.4% in Q2 2026 due to lower interest income and higher interest expense.
• Cash and cash equivalents decreased from $74.5 million at the end of 2025 to $40.2 million at the end of Q2 2026.
• Accounts payable increased by $20.3 million, and accrued insurance increased by $10.4 million.
• Treasury stock increased by $291.9 million due to stock repurchases.

Risks

• Macroeconomic trends such as inflation, tariffs, and the impact of geopolitical events on fuel prices may adversely affect net sales and profitability.
• The VITAS segment operates in a heavily regulated industry and is subject to inquiries, investigations, penalties, and lawsuits.
• VITAS has significant accounts receivable from Medicare and Medicaid programs, representing approximately 76% of consolidated net accounts receivable.
• Disruptions from VITAS's main pharmacy and medical supply vendors could adversely impact operations.
• The company has $140.0 million of variable rate debt outstanding, exposing it to interest rate fluctuations.
• The company is subject to various lawsuits and claims in the normal course of business.

Future Outlook

The company anticipates that its operating income and cash flows will be sufficient to operate its business and meet any commitments for the foreseeable future. Management is continuing to evaluate macroeconomic trends and their potential effects, as well as the ability to offset cost increases through pricing actions and cost savings efforts for fiscal year 2027 planning.

Management Comments

• We do not expect a material negative effect on our net sales or profitability for the remainder of fiscal year 2026.
• We are continuing to evaluate these factors and their potential effects as well as our ability to potentially offset all or a portion of cost increases through pricing actions and cost savings efforts for fiscal year 2027 planning.
• Management believes its liquidity and sources of capital are satisfactory for the Company's needs in the foreseeable future.

Industry Context

StockSavvy.ai notes that Chemed's performance reflects a bifurcated market: the stable, growing demand for hospice care services (VITAS) contrasts with the more cyclical, price-sensitive home services sector (Roto-Rooter). The company's ability to leverage its scale in both segments is key to navigating economic pressures.

Comparison to Industry Standards

• VITAS's gross margin of 23.8% in Q2 2026 is a significant improvement from 19.1% in Q2 2025, potentially outperforming industry benchmarks that often face pressure from regulatory changes and reimbursement rates.
• Roto-Rooter's gross margin of 50.4% in Q2 2026 is robust for the home services sector, indicating strong pricing power and operational efficiency compared to smaller, regional competitors.
• The increase in days of care at VITAS (6.1%) suggests a growing demand for hospice services, aligning with broader demographic trends of an aging population, a trend seen across major healthcare providers globally.

Legal Proceedings

• VITAS was involved in an audit by the OIG's Office of Audit Services regarding elevated level-of-care hospice services, resulting in a demand letter for $50.3 million, which was later reduced to a de minimis amount following an ALJ ruling.
• Multiple class action lawsuits were filed against VITAS following a cybersecurity incident and data breach on October 24, 2025; these have been settled for a non-material amount covered by insurance.

Stakeholder Impact

• Shareholders benefit from increased net income, EPS growth, and ongoing share repurchase programs.
• Employees are critical resources, with management noting normal salary increases and incentive compensation.
• Customers of VITAS receive hospice care services, with the company noting charity care costs.
• Suppliers for VITAS (pharmacy and medical supplies) may face potential disruption risks if the company's main vendors experience issues.

Next Steps

• Continue to monitor macroeconomic trends, inflation, tariffs, and geopolitical impacts on net sales and profitability.
• Evaluate ability to offset cost increases through pricing actions and cost savings efforts for fiscal year 2027 planning.
• Continue to manage liquidity and capital resources, considering share repurchases, debt repurchases, acquisitions, and dividends.

Key Dates

Recommendation

The company demonstrates solid performance with revenue and profit growth, particularly in its stable VITAS segment. However, increasing corporate expenses, a decrease in cash and cash equivalents, and the inherent risks in the regulated healthcare and cyclical home services sectors warrant a cautious 'hold' rating. Further clarity on the long-term impact of macroeconomic factors and successful integration of recent acquisitions would be needed for a stronger recommendation.

Keywords

hospice care, plumbing services, drain cleaning, water restoration, healthcare services, home services, revenue growth, profitability